This content is from: Patents

In-house roundup: Simulations should be patentable; procedure rules may restrict appeals; trade secrets after Alice; Medicines Patent Pool interview

Managing IP rounds up the latest news and analysis from patent-focused businesses


Making simulations non-patentable ‘big step back for European industry’ 

The EPO Enlarged Board of Appeal’s decision in G1/19 is coming, and in-house counsel say it is important for their businesses and European innovation that computer-implemented simulations be patent eligible. Read More... 

New EPO procedural rules may restrict appeals but guidelines are ‘slight recipe change’ 

With the new examination guidelines and procedure rules coming into force, businesses reveal their views on changes to the ‘hope to succeed’ criteria and the earlier-communicated streamlining of the appeals process. Read more... 

Alice five years on: trade secrets are still popular alternative to patents 

Businesses say they have increasingly turned to trade secrets since the 2014 SCOTUS decision because of the sustained ambiguity around Section 101; but add that there are challenges along that path too. Read more... 

Medicines Patent Pool model increases access to medicine with solid business case 

In an exclusive interview with executive director Charles Gore, Patent Strategy learns how the MPP model increases access to HIV medicine while allowing innovators to benefit financially. Read more... 

The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.

© 2020 Euromoney Institutional Investor PLC. For help please see our FAQs.


Instant access to all of our content. Membership Options | One Week Trial